Search the Newsreel

Sarepta forecasts $1.2B-$1.3B 2026 net product revenue as Cohort 8 12-week data shifts to Q1 2027

Earnings Call Insights: Sarepta Therapeutics (SRPT) Q2 2026 MANAGEMENT VIEW * “This is my first earnings call as CEO of Sarepta...” and “we have narrowed 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, with a mid-point being the appropriate reference,” …

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform Evolution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline

The market expects Sarepta Therapeutics (SRPT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …

Sarepta Therapeutics Names Michael Severino As CEO; Shares Rise In Pre-Market

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT), a company focused on genetic medicine for rare diseases, has appointed Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino will also join the company's Board of Directors, succeeding Doug Ingram, who is retiring and …

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround. The company on Monday announced that Michael Severino, …

Sarepta Skids After A Rival Clears A Key Hurdle In The Duchenne Space

Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients. Continue Reading

Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits?

Dyne Therapeutics stock briefly jumped Monday after the FDA agreed to review the company's muscular dystrophy drug. Continue Reading

BDR Sarepta Therapeutics - S1RP34 - Resultados, Dividendos, Cotação e Indicadores